Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P Grigg

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Transplantation and Cellular Therapy|June 6, 2026
Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell TransplantationNermen Tawfik, Ashleigh P Scott, Catelyn Cashion, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Transplantation and Cellular Therapy|June 6, 2026
Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell TransplantationNermen Tawfik, Ashleigh P Scott, Catelyn Cashion, et al.
Blood|December 19, 2014
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Michael P Osborn, Deborah L White, et al.
Haematologica|March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionNaranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Pageof 4